货号:A1174800
同义名:
MK-3475; Lambrolizumab
Pembrolizumab是一种人源化IgG4单克隆抗体,通过与PD-1受体结合来阻止其与配体结合。Pembrolizumab具有用于多种癌症(如黑色素瘤、非小细胞肺癌)研究的潜力。
HazMat Fee + There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
| Type | HazMat fee for 500 gram (Estimated) |
| Excepted Quantity | USD 0.00 |
| Limited Quantity | USD 15-60 |
| Inaccessible (Haz class 6.1), Domestic | USD 80+ |
| Inaccessible (Haz class 6.1), International | USD 150+ |
| Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
| Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | PD-1 ↓ ↑ | PD-1/PD-L1 ↓ ↑ | PD-1/PD-L1 interaction ↓ ↑ | PD-L1 ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SR0987 | ✔ | 99% | |||||||||||||||||
| Pembrolizumab | ✔ | 98% | |||||||||||||||||
| Camrelizumab | ✔ | 95% | |||||||||||||||||
| Spartalizumab | ✔ | 95% | |||||||||||||||||
| BMS-1001 |
+
PD-1/PD-L1, EC50: 253 nM |
+
PD-1/PD-L1, EC50: 253 nM |
98% | ||||||||||||||||
| INCB086550 |
++
PD-1/PD-L1, IC50: <10 nM |
++
PD-1/PD-L1, IC50: <10 nM |
98% | ||||||||||||||||
| BMS-1 |
++
PD-1/PD-L1 interaction, IC50: 0.006 μM |
99%+ | |||||||||||||||||
| BMS-202 |
+
PD-1/PD-L1 interaction, IC50: 0.018 μM |
99%+ | |||||||||||||||||
| PD-1/PD-L1-IN 3 |
+++
PD-1/PD-L1 interaction, IC50: 5.6 nM |
98+% | |||||||||||||||||
| Nivolumab |
+++
PD-1/PD-L1 interaction, IC50: 2.52 nM |
95% | |||||||||||||||||
| BMS-1166 |
+++
PD-1/PD-L1 interaction, IC50: 1.4 nM |
99%+ | |||||||||||||||||
| Durvalumab |
++++
PD-1/PD-L1 interaction, IC50: 0.1 nM |
95% | |||||||||||||||||
| Evixapodlin |
++++
PD-1/PD-L1, IC50: 0.213 nM |
95% | |||||||||||||||||
| CA-170 | ✔ | 97% (contains 2.7% ethanol) | |||||||||||||||||
| Atezolizumab |
+++
hPD-L1, Kd: 0.4 nM |
99% | |||||||||||||||||
| AUNP-12 | ✔ | 98% | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | Product Name: Pembrolizumab Cross-reactivity: Human,Cynomolgus Organism:Human Target name: PDCD1 / PD-1 / CD279 Recommended Dilution Buffer: Sterile PBS or 0.9% saline for reconstitution/dilution. It is recommended to use the reconstituted/diluted product within one month. Formulation: 100 mM Pro-Ac,20 mM Arg,pH5.0 Endotoxin: < 0.001EU/μg, determined by LAL method. Purity: >95%. Determined by SDS-PAGE Purification: Purified, Protein A, affinity column Storage: -80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles. Isotype: IgG4SP-Kappa |
| Concentration | Treated Time | Description | References | |
| SFMCs (21-day culture) | 5 μg/mL | 21 days | To investigate the effect of Pembrolizumab on TRAP secretion in SFMCs, results showed Pembrolizumab did not significantly increase TRAP secretion (P = 0.28). | Arthritis Res Ther. 2022 Feb 14;24(1):43 |
| Human EA.hy926 endothelial cells | 100 μg/ml | 24 hours | Study the toxic effect of Pembrolizumab on endothelial cells, finding that atorvastatin could prevent this toxicity | Basic Res Cardiol. 2025 Feb;120(1):263-286 |
| Splenocytes | 0-100 μg/ml | 24 hours | Assess the effect of ICIs on immune cells, finding that Pembrolizumab at high doses induced increased Th17-type cytokine expression | Basic Res Cardiol. 2025 Feb;120(1):263-286 |
| Human spermatozoa | 1-100 ng/mL | 4 hours | To evaluate the effect of Pembrolizumab on human sperm motility. Results showed that Pembrolizumab significantly reduced sperm motility at concentrations of 10 ng/mL and above. | Front Pharmacol. 2025 Mar 31;16:1534975 |
| PBMCs | 5 µg/mL pembroliz µMab and 1 µg/mL rhGal-3 | 48 hours | Investigate the effect of Gal-3 and pembrolizumab on IL-2 production, results showed Gal-3 significantly decreased IL-2 production and pembrolizumab could not rescue it | J Immunother Cancer. 2024 Oct 2;12(10):e009952 |
| FLS-PBMC co-cultures | 5 μg/mL | 48 hours | To investigate the effect of Pembrolizumab on MMP-3 production in FLS-PBMC co-cultures, results showed Pembrolizumab did not significantly increase MMP-3 production (P = 0.76). | Arthritis Res Ther. 2022 Feb 14;24(1):43 |
| PBMCs from healthy controls | 5 μg/mL | 48 hours | To investigate the effect of Pembrolizumab on MCP-1 production in PBMCs from healthy controls, results showed Pembrolizumab did not significantly increase MCP-1 production (P = 0.43). | Arthritis Res Ther. 2022 Feb 14;24(1):43 |
| Peripheral blood mononuclear cells (PBMCs) | 5 μg/mL | 48 hours | To investigate the effect of Pembrolizumab on MCP-1 production in PBMCs, results showed Pembrolizumab did not significantly increase MCP-1 production (P = 0.77). | Arthritis Res Ther. 2022 Feb 14;24(1):43 |
| Synovial fluid mononuclear cells (SFMCs) | 5 μg/mL | 48 hours | To investigate the effect of Pembrolizumab on MCP-1 production in SFMCs, results showed Pembrolizumab significantly increased MCP-1 production (P = 0.0031). | Arthritis Res Ther. 2022 Feb 14;24(1):43 |
| Administration | Dosage | Frequency | Description | References | ||
| Human Pdcd1 transgenic mice | B16F10-R tumor model | Intravenous injection | 10 mg/kg | Twice a week | To investigate the role of COX2 in acquired resistance to anti-PD-1 treatment | Cancers (Basel). 2022 Aug 26;14(17):4134 |
| C57BL6/J male mice | Nontumor-bearing mice | Intraperitoneal | 2 mg/kg | Weekly for 2 and 5 weeks | Establish a model of Pembrolizumab-induced cardiotoxicity, finding that Pembrolizumab caused coronary endothelial and diastolic dysfunction at 2 weeks and systolic dysfunction at 5 weeks | Basic Res Cardiol. 2025 Feb;120(1):263-286 |
| CAS号 | 1374853-91-4 |
| 分子量 | 146.6 kDa |
| SMILES Code | NONE |
| MDL No. | N/A |
| 别名 | MK-3475; Lambrolizumab |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C:3-6个月-80°C:24个月 |
沪公网安备 31011702889066号
沪ICP备2024050318号-1